PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
2 意见
• 07/14/23
0
0
嵌入
Visit http://www.ecancer.org for more
Dr Calvo (START Madrid, Madrid, Spain) talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论